UK Medicines Information
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck - guidance (TA473)
Information type:
Drug best practice guidance
Source:
National Institute for Health and Care Excellence
Specialities:
Cancers
Summary
NICE recommends cetuximab in combination with platinum-based chemotherapy as an option for treating recurrent or metastatic squamous cell cancer of the head and neck in adults if the cancer started in the oral cavity and it is provided in line with the commercial access agreement
UKMi comment
This guidance is a Cancer Drugs Fund reconsideration of (and replaces) TA172.
Related links: